CMC Biopharmaceuticals and Biotest Announce Manufacturing Agreement for BT-062 Antibody

By:Diana Morgan

Copenhagen, Denmark; February 5 2007 – CMC Biopharmaceuticals A/S, a Copenhagen based contract manufacturing organization, and Biotest AG a developer of pharmaceutical, biotherapeutic and diagnostic products based in Dreieich, Germany announced today that they have entered into a manufacturing agreement for the cGMP production of BT-062 antibody. The product will be manufactured at CMC’s facility in Copenhagen, Denmark, for
clinical supply.

Read the entire pdf press release